Moderna (NASDAQ:MRNA) PT Raised to $151.00 at UBS Group

Moderna (NASDAQ:MRNA) had its target price hoisted by UBS Group from $143.00 to $151.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price target indicates a potential upside of 23.88% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. HSBC restated a “reduce” rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Royal Bank of Canada boosted their price objective on Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Finally, Oppenheimer raised their target price on Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $126.89.

Moderna Stock Up 0.7 %

Shares of NASDAQ:MRNA opened at $121.89 on Tuesday. The firm has a market cap of $46.71 billion, a P/E ratio of -7.78 and a beta of 1.57. Moderna has a 12-month low of $62.55 and a 12-month high of $142.79. The business has a fifty day simple moving average of $106.59 and a 200 day simple moving average of $95.24. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The firm’s revenue was down 91.0% compared to the same quarter last year. During the same period last year, the company earned $0.19 earnings per share. Analysts predict that Moderna will post -7.47 earnings per share for the current year.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total value of $1,663,800.00. Following the transaction, the director now owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the transaction, the director now directly owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 647 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at approximately $406,651. The disclosure for this sale can be found here. Insiders sold a total of 139,954 shares of company stock valued at $14,822,576 over the last three months. Corporate insiders own 15.20% of the company’s stock.

Hedge Funds Weigh In On Moderna

Hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James & Associates lifted its holdings in Moderna by 20.3% during the third quarter. Raymond James & Associates now owns 186,342 shares of the company’s stock worth $19,247,000 after acquiring an additional 31,423 shares during the period. Brown Advisory Inc. increased its position in shares of Moderna by 88.3% during the 3rd quarter. Brown Advisory Inc. now owns 6,142 shares of the company’s stock valued at $634,000 after purchasing an additional 2,880 shares during the last quarter. Mackenzie Financial Corp raised its stake in shares of Moderna by 3.2% during the 3rd quarter. Mackenzie Financial Corp now owns 68,043 shares of the company’s stock worth $7,014,000 after purchasing an additional 2,135 shares during the period. IFM Investors Pty Ltd boosted its holdings in shares of Moderna by 4.6% in the 3rd quarter. IFM Investors Pty Ltd now owns 65,752 shares of the company’s stock worth $6,792,000 after buying an additional 2,885 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Moderna by 18.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 409,423 shares of the company’s stock valued at $42,289,000 after buying an additional 64,344 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.